Drugs in ATC Class V08AD

Up to Top Level ATC Classes

Up to V - Various

Up to V08 - CONTRAST MEDIA

Up to V08A - X-RAY CONTRAST MEDIA, IODINATED

Drugs in ATC Class: V08AD - Non-watersoluble X-ray contrast media

Tradename	Generic Name
DIONOSIL AQUEOUS	propyliodone
DIONOSIL OILY	propyliodone

Market dynamics and patent landscape for ATC Class V08AD non-watersoluble X-ray contrast media

Last updated: June 6, 2026

Non-watersoluble X-ray contrast media in ATC class V08AD cover iodinated, oil- or water-insoluble agents used mainly for angiography, visceral imaging, and select embolization and interventional procedures. The commercial value pool is shaped by (1) regulatory and compendial acceptance of iodine concentration and viscosity targets, (2) patient safety and tolerability (especially risk of neurotoxicity and injection site reactions where applicable), (3) manufacturing controls that protect particle/crystal size and stability, and (4) patent estates that are often fragmented across scaffolds (iodinated aromatic cores), specific solubilizing/excipient systems, and process steps. Patent coverage for this class is dominated by legacy small-molecule compositions and downstream formulation or process patents, with periodic extensions via polymorph control, production methods, and device-administration formats.

What patents protect non-watersoluble iodinated X-ray contrast media in ATC V08AD?

Answer (composition-level): Patents protecting V08AD products typically fall into four buckets: (i) iodinated aromatic drug substances and intermediate routes, (ii) formulation and composition claims tied to non-watersoluble carrier systems (e.g., oils, ethyl esters, lipophilic vehicles) and stabilizers, (iii) process/manufacturing claims controlling purity, particle/crystal properties, and residual solvent/water, and (iv) method-of-use claims tied to specific imaging indications and route of administration.

Which active ingredients most commonly anchor V08AD patent estates?

V08AD is an ATC bucket rather than a single INN. The estate will vary by market and by the branded compound available in that geography. Common anchors for non-water-soluble iodinated agents include iodinated oils and related non-aqueous contrast materials used for angiography and selective embolization-adjacent imaging. In practice, most enforceable IP sits with the original NDA/BLA holders for those specific products, then with formulation and process assignees who defend manufacturing know-how and product specs.

What formulation elements are usually claimed in V08AD patents?

Featured claim patterns in this class include:

• Non-aqueous carrier system identity and ratios (oil type, ester content, and viscosity modifiers)
• Stabilizer and antioxidant package (where required to address iodine stability and oxidation)
• Solute concentration and target iodine content per mL
• Particle/crystal size distributions or “substantially uniform” solids where the product is not fully molecularly dissolved
• Rheology targets and temperature-dependent flow characteristics
• Residual solvent limits and impurity specifications
• Container closure and compatibility (especially if the product is sensitive to leachables or adsorption)

What manufacturing-process patents appear most frequently?

Process claims are often more defensible than composition claims once the core chemical is old. Typical scope includes:

• Purification steps for iodine-containing intermediates and final drug substance
• Crystallization control (temperature profiles, seeding, and hold times)
• Milling/grinding or homogenization procedures (where solid dispersion is involved)
• Filtration and sterilization strategy that preserves particle characteristics
• Solvent exchange and water removal logic to protect “non-watersoluble” behavior
• Packaging-administration compatibility (fill-finish steps and container selection)

Geographic coverage: where do most V08AD estates matter?

Commercial risk and litigation focus concentrate where interventional radiology and angiography demand is high and patent enforcement is active:

• US: composition/process patents and Orange Book listings (when applicable to the specific product) drive generic timing.
• EU: national validation and coordinated EP litigation shape injunction risk and launch timing.
• UK: active national post-Brexit enforcement against validated EPs.
• JP: product patents and procedural IP can block supply and delay generic substitution.
• CN/IN: filings exist but the enforceability and litigation posture vary by product and assignee strategy.

When does V08AD non-watersoluble contrast media lose exclusivity?

Answer (timeline-level): In this class, exclusivity is rarely a single date. Market entry timing usually depends on the last expiring patent in the specific product’s independent claim set (composition, process, and sometimes device/administration), plus any remaining regulatory data exclusivity tied to the original authorization and any later-granted improvements.

How to model exclusivity windows for a V08AD portfolio

For each specific non-watersoluble contrast product, model four clocks:

1. Primary composition patent expiry
2. Method-of-manufacture or purification patent expiry
3. Formulation/excipient optimization expiry (often later than composition)
4. Regulatory exclusivity (if applicable in the jurisdiction)

Because many V08AD products are older, the most relevant launch risk for generic or follow-on suppliers tends to come from process/formulation patents rather than from the core iodine scaffold.

What generic entry risks exist for non-watersoluble V08AD agents?

Risks for generics and follow-on products include:

• Patents tied to specific production parameters that are hard to design around without changing product spec
• Claims that cover impurity profiles and residual solvent thresholds
• Claims that cover viscosity, iodine density, and stability in the non-aqueous environment
• Selection patents for stabilizer systems used to meet shelf-life acceptance

Launch timing is often delayed by “insufficient design-around” at the process level, even when composition patents are expired.

What formulations are protected by V08AD patents: oil-based vehicles, stabilizers, and viscosity targets?

Answer (formulation): V08AD patents commonly protect the non-aqueous vehicle system and the stabilizer package that preserves injectable stability, viscosity, and tolerability. The enforceability often hinges on objective product parameters that can be tested (iodine concentration, viscosity at specified temperatures, impurity profile, and stability).

What are typical proprietary formulation “dials” in this class?

• Iodine content and density: claims often anchor to specific mg I/mL targets and acceptable ranges
• Vehicle identity: oil type and ester composition affect dissolution/dispersion behavior
• Viscosity control: claimed ranges at set temperatures to manage injection force
• Stability and oxidation: antioxidant systems and exclusion of reactive impurities
• Sterility assurance approach: process claims covering filtration and sterility strategy
• Container compatibility: adsorption and leachables controls

How do formulation patents affect interchangeability?

Even if a follow-on meets labeled indications, formulation patents can block:

• Approved manufacturing changes that would be needed to reduce risk
• Establishment of “sameness” for regulatory comparability if the original relies on a unique excipient profile or controlled particle properties

Which companies hold the patent estates for ATC V08AD non-watersoluble X-ray contrast media?

Answer (portfolio reality): Patent ownership is typically split between (i) originators of the specific iodinated non-watersoluble contrast media and (ii) later entrants who acquired or licensed specific dossiers and improvements. In practice, assignees are usually large branded imaging companies and their IP-holding affiliates, plus specialized pharmaceutical formulation/process developers in certain regions.

How to evaluate estate strength by assignee

Business-use scoring for each assignee’s V08AD estate should prioritize:

• Number of active composition/process patents per product
• Remaining life on the latest-filed formulation and process grants
• Whether claims cover product parameters that are measurable and required for approval
• History of infringement positions and settlement terms in related contrast media disputes

What patent litigation affects non-watersoluble X-ray contrast media?

Answer (litigation posture): Contrast media IP litigation typically targets design-around failures in manufacturing and formulation rather than purely chemical scaffold similarity. Where challenged, defendants focus on manufacturing differences, impurity profiles, and regulatory-grade comparability.

Typical litigation themes in V08AD-type cases

• “Product-by-process” infringement arguments
• Allegations that follow-on producers use similar purification and crystallization regimes
• Dispute over whether viscosity and iodine density ranges fall within claim scope
• Container closure and stability-related arguments where formulation is claimed by structure and parameter

How settlements usually structure risk

Settlements in this category often include:

• Narrow launch timing windows
• Supply limitations or non-infringing process obligations
• Stipulated carve-outs for specific indications or dosage forms (when relevant)

What is the Orange Book status of V08AD non-watersoluble contrast media?

Answer (regulatory listing): Orange Book status is product-specific. For V08AD, the relevant listings depend on which specific non-watersoluble contrast media are authorized as US drug products and how each is categorized. In the US, patent listings and exclusivity windows drive FDA-related generic timing and Paragraph IV leverage, when applicable.

What to expect in US listings for this class

• Drug-substance and product patents listed for eligible NDA products
• Formulation and method-of-use patents may appear if they were used to support approval
• Orange Book coverage may be incomplete if certain components are covered only under patents not listed for the specific US approval

How does V08AD compare with other X-ray contrast ATC classes on patent risk?

Answer (relative): Non-watersoluble iodine contrast media tend to have stronger process/formulation defendability than fully water-soluble agents because vehicle system, viscosity, and stability management are tightly tied to manufacturing controls and product specifications. By contrast, water-soluble agents may have more straightforward composition similarity, shifting design-around attention to concentration and excipients.

Key comparison axes

• Solubility-driven formulation complexity
• Stability challenges (oxidation and compatibility)
• Rheology/injection parameter control
• Packaging compatibility needs

What generic entry scenarios are most likely for V08AD?

Answer (launch pathways): The most plausible generic or follow-on entry strategies for non-watersoluble iodinated contrast media are:

1. Composition-expired, process-design-around entry
2. Product-family entry where a company develops a new formulation that stays outside claimed parameter ranges
3. In-license entry via acquisition of a product dossier with existing manufacturing controls that reduce infringement risk
4. Limited launch focusing on specific strengths or dosage forms if patents are narrow on those attributes

Manufacturing/IP barriers that block entry

• Achieving the same iodine density and viscosity under required temperatures without using the patented process parameters
• Matching impurity profiles and residual solvent limits mandated by regulatory acceptance
• Reproducibly controlling particle characteristics if any solid dispersion exists

Commercial dynamics: pricing power, supply constraints, and hospital adoption

Answer (market structure): V08AD demand is driven by interventional radiology, angiography workflows, and procedure volumes. Pricing power depends on:

• Availability and reliability of supply
• Adverse-event profile and clinician familiarity
• Tendering practices and switching friction
• Reimbursement stability and multisource availability

What moves revenue in this class

• Procedure volumes and imaging mix (more interventions can expand tonnage of contrast used)
• Contracting and tender cycles that determine switching windows
• Inventory management and manufacturing downtime impacts
• Safety signal management: label changes can re-shape utilization patterns

Key takeaways

• V08AD non-watersoluble X-ray contrast media IP is usually fragmented across composition, formulation/excipient, and manufacturing process patents; defensibility often sits in process and product-parameter claims.
• Exclusivity is a portfolio-level timing issue per specific product, not a single ATC-class date. The last expiring formulation/process patents typically govern generic/follow-on entry.
• Generic risk is highest where patents claim viscosity/iodine density/stability parameters and where those parameters are tightly linked to protected manufacturing steps.
• Orange Book status and Paragraph IV leverage are product-specific, so timing and challenge strategy depends on the exact marketed NDA product(s) in the US.

FAQs

1. Do V08AD non-watersoluble contrast media patents more often target excipients or manufacturing processes?
2. How do viscosity and iodine density claim ranges affect design-around strategies for follow-on contrast products?
3. What evidence is typically used in infringement disputes over product-by-process claims in contrast media?
4. Which jurisdictions most strongly influence exclusivity and enforcement for non-watersoluble iodinated contrast agents?
5. When generic substitution is blocked in V08AD, is it usually due to US patent listings, device/administration claims, or process controls?

References (APA)

1. WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC classification. World Health Organization.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. EPO. (n.d.). European Patent Register. European Patent Office.
4. FDA. (n.d.). Drug Approval Reports / Drug Trials Snapshots. U.S. Food and Drug Administration.